ALACHUA, Fla.--(EON: Enhanced Online News)--Banyan Biomarkers, Inc. will partner with Emory University through a grant from the National Institutes of Health to measure biomarkers in the blood of traumatic brain injury (TBI) patients. The five-year grant of $2.2 million was awarded to Michael Frankel, MD, Professor of Neurology at Emory School of Medicine, with partners Banyan Biomarkers, Inc., the Medical University of South Carolina, the University of Pittsburgh and the University of Michigan. The research team will study biomarkers in the blood of TBI patients enrolled in the phase III clinical trial, ProTECT III (Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment), which is assessing the efficacy of progesterone in the treatment of TBI.
“Ultimately, we envision that biomarkers will have the potential to significantly improve the ability to diagnose a traumatic brain injury and improve clinical outcomes for patients”
“We will study the ability of biomarkers to monitor the efficacy of progesterone in this clinical trial,” stated Dr. Frankel. “Ultimately, we envision that biomarkers will have the potential to significantly improve the ability to diagnose a traumatic brain injury and improve clinical outcomes for patients,” stated Andreas Jeromin, PhD, Director of Business Development and Analytical Service Department for Banyan Biomarkers, Inc.
According to the Centers for Disease Control and Prevention, approximately 1.4 million Americans visit an emergency department as a result of TBI each year, of which 275,000 are hospitalized and 52,000 deaths occur. The direct and indirect medical costs associated with TBI have been estimated to be approximately $60 billion.
The ProTECT III trial a is multi-site NIH-sponsored clinical study enrolling 1,140 patients at 17 centers nationwide under the leadership of David Wright, MD, Professor of Emergency Medicine at Emory University. Progesterone is a naturally occurring hormone in the body, which has shown efficacy in earlier pilot clinical trials.
About Banyan Biomarkers
Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. Banyan Biomarkers has a licensing agreement with the University of Florida for exclusive global use of technology related to this product. To learn more about Banyan Biomarkers, Inc., visit http://www.banyanbio.com.